TY - JOUR
T1 - Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma
T2 - A 4 week randomized multicentre controlled trial
AU - Yoo, Se Hwa
AU - Park, Sung Hak
AU - Song, Jeong Sup
AU - Kang, Kyung Ho
AU - Park, Choon Sik
AU - Yoo, Jee Hong
AU - Choi, Byoung Whui
AU - Hahn, Myung Ho
PY - 2001/5/9
Y1 - 2001/5/9
N2 - Objective: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. Methodology: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with β2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. Results: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n=98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of β2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 ± 10.1 L/min at baseline, 394.5 ± 10.1 at week 2, 396.3 ± 10.4 at week 4). There were no serious adverse reactions. Conclusion: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.
AB - Objective: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. Methodology: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with β2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. Results: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n=98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of β2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 ± 10.1 L/min at baseline, 394.5 ± 10.1 at week 2, 396.3 ± 10.4 at week 4). There were no serious adverse reactions. Conclusion: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.
KW - Leukotriene receptor antagonist
KW - Mild-to-moderate asthma
KW - Pranlukast
KW - Randomized clinical trial
UR - http://www.scopus.com/inward/record.url?scp=0035026972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035026972&partnerID=8YFLogxK
U2 - 10.1046/j.1440-1843.2001.00291.x
DO - 10.1046/j.1440-1843.2001.00291.x
M3 - Article
C2 - 11264758
AN - SCOPUS:0035026972
SN - 1323-7799
VL - 6
SP - 15
EP - 21
JO - Respirology
JF - Respirology
IS - 1
ER -